There are 511 resources available
409P - Investigation of synergistic effects in trials of combination therapies with immune-checkpoint inhibitors in advanced esophageal squamous cell carcinoma
Presenter: Jun Okui
Session: Poster Display session
Resources:
Abstract
410P - An evaluation of the service provision and dietetic advice provided within UK and Ireland for oesophageal stents
Presenter: Lindsey Foulkes
Session: Poster Display session
Resources:
Abstract
411P - Time-to-treatment initiation and survival in patients with locally advanced esophageal cancer
Presenter: Efrat Gur
Session: Poster Display session
Resources:
Abstract
412P - Survival outcome and safety of different treatment models in patients with oligometastatic esophageal cancer with only distant lymph node metastasis
Presenter: Xiaolin Qiu
Session: Poster Display session
Resources:
Abstract
413P - Following planned pre-operative (pre-op) chemo-radiotherapy (CRT) for squamous cell cancer (SCC) of the esophagus (eso), why do some patients not undergo surgery (sx)? A service evaluation from a tertiary care hospital in a Low-Middle Income Country (LMIC
Presenter: Shaleen Kumar
Session: Poster Display session
Resources:
Abstract
414P - A study on neoadjuvant chemoradiotherapy: Cross-protocol in a tertiary care centre in India
Presenter: Kavya Pamidi
Session: Poster Display session
Resources:
Abstract
415P - Safety and short-term efficacy of neoadjuvant FLOT therapy in patients with resectable locally advanced esophageal squamous cell carcinoma
Presenter: Yuri Yoshinami
Session: Poster Display session
Resources:
Abstract
416P - Evolutionary and immune microenvironment dynamics determine response to neoadjuvant treatment of oesophageal adenocarcinoma
Presenter: Melissa Barroux
Session: Poster Display session
Resources:
Abstract
418P - A PET/CT image-based deep learning approach for precise survival prognosis and clinical management of treatments in patients with esophageal carcinoma
Presenter: Jian-Hua Liu
Session: Poster Display session
Resources:
Abstract
419P - Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Additional analyses from 4-year (y) follow-up (FU) of CheckMate 649
Presenter: Lucjan Wyrwicz
Session: Poster Display session
Resources:
Abstract